Table 2

Immunotherapies in development for the treatment of non-Hodgkin lymphoma

TrialAgents investigatedAgent descriptionPrimary outcome for assessment
POLARGO (NCT04182204)Polatuzumab vedotin-piiq+R-GemOx vs R-GemOx for R/R DLBCLADCRate of adverse events, OS
POLARIX (NCT03274492)Polatuzumab vedotin-piiq+R-CHP vs R-CHOP for first-line DLBCLADCPFS
BELINDA (NCT03570892)Chemotherapy+tisagenlecleucel vs Chemotherapy+autoSCT for R/R B cell NHLCAR T cellEFS
TRANSCEND-NHL-001 (NCT02631044)Lisocabtagene maraleucelCAR T cellTreatment-related adverse events, dose-limiting toxicities, ORR
TRANSFORM (NCT03575351)SOC (R-DHAP, R-ICE, or R-GDP; followed by HDCT (BEAM) and stem cell transplant) vs JCAR017 (lisocabtagene maraleucel) for R/R B cell NHLCAR T cellEFS
ZUMA-5 (NCT03105336)Axicabtagene ciloleucel+cyclophosphamide+fludarabine for R/R indolent NHLCAR T cellORR
ZUMA-7 (NCT03391466)Axicabtagene ciloleucel vs SOC for R/R DLBCLCAR T cellEFS
NIVEAU (NCT03366272)Nivolumab+R-GemOx vs R-GemOx for R/R B cell NHLICIPFS
NCT03016000Thalidomide maintenance for DLBCLIMiDRelapse-free survival
ROBUST (NCT02285062)Lenalidomide+R-CHOP vs placebo+R-CHOP for first-line DLBCLIMiDPFS
B-MIND (NCT02763319)BR vs MOR208 (tafasitamab-cxix)+bendamustine for R/R DLBCLmAbPFS
NCT01974440Ibrutinib+BR or R-CHOP vs placebo+BR or R-CHOP for R/R indolent NHLmAb and BTKiPFS
NCT04002297Zanubrutinib+rituximab vs BR for first-line MCLmAb and BTKiPFS
NCT04212013Ibrutinib+rituximab vs Ibrutinib+placebomAb and BTKiCR rate
CHRONOS-3 (NCT02367040)Copanlisib+rituximab vs placebo for R/R B cell NHLmAb and PI3KiPFS
CHRONOS-4 (NCT02626455)Copanlisib+rituximab-chemotherapy vs placebo+rituximab-chemotherapy for R/R indolent NHLmAb and PI3KiRate of dose-limiting toxicities/AEs, PFS
UNITY-NHL (NCT02793583)TGR-1202+ublituximab vs TGR-1202 vs TGR-1202+ublituximab+bendamustine for R/R NHLmAb and PI3KiORR
NCT02320292Rituximab+IT vs rituximab for first-line FLRadioimmunotherapyCR rate
  • ADC, antibody-drug conjugate; AEs, adverse events; AutoSCT, autologous stem cell transplant; BR, bendamustine, rituximab; BTKi, Bruton’s tyrosine kinase inhibitor; CAR, chimeric antigen receptor; CR, complete response; DA-R-EPOCH, dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; DLBCL, diffuse large B cell lymphoma; EFS, event-free survival; FL, follicular lymphoma; ICI, immune checkpoint inhibitor; IMiD, immunomodulatory drug; mAb, monoclonal antibody; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PI3Ki, phosphoinositide 3-kinase inhibitor; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHP, rituximab, cyclophosphamide, doxorubicin, prednisone; R-GemOx, rituximab, gemcitabine, oxaliplatin; R/R, relapsed or refractory; SOC, standard of care.